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1. Conduct	 a	 Cochrane	 systematic	 review	 to	 assess	 the	 evidence	 base	 for	 the	
management	of	distal	intestinal	obstruction	syndrome	in	cystic	fibrosis,	on	one	or	
both	of	the	following	subjects:	
i.)	 Interventions	 for	 preventing	 distal	 intestinal	 obstruction	 syndrome	 in	 cystic	
fibrosis.		
ii.)	 Interventions	 for	 treating	 distal	 intestinal	 obstruction	 syndrome	 in	 cystic	
fibrosis.			






This	 chapter	 provides	 information	 on	 CF,	 focussing	 on	 its	 epidemiology,	 historical	




CF	 is	 an	autosomal	 recessive,	 chronic,	progressive	disease	 in	which	 the	 sufferer	 is	born	
with	 a	 mutation	 in	 the	 gene	 encoding	 the	 Cystic	 Fibrosis	 Trans-membrane	 Regulator	
Protein	 (CFTR).	Normally,	 this	protein	 translates	 into	an	 ion	channel	 responsible	 for	 the	
movement	of	anions	 (notably	chloride	 ions	and	thiocyanate	 ions)	out	of	epithelial	 cells,	






complications	 include	pancreatic	 insufficiency,	 disturbances	 in	 gastrointestinal	 function,	
nutritional	deficiencies	and	 reproductive	 issues	 (1).	These	 result	 in	a	 reduced	quality	of	









for	 diseases,	 CF	 sufferers	 were	 thought	 by	many	 to	 be	 cursed.	 The	 common	mode	 of	




record	 of	 the	 disease	 dates	 back	 to	 1838.	 This	 was	 a	 post-mortem	 report	 by	 Austrian	





London	 physician,	 titled	 it	 “the	 coeliac	 affection”.	 He	 described	 it	 as	 a	 “chronic	




Anderson,	 in	 1938.	 	 Anderson	 observed	 that	 a	 few	 patients,	 who	 had	 seemingly	
responded	 to	 their	 treatment	 for	 coeliac	 disease,	 lacked	 healthy	 pancreatic	 tissue	 on	
	
4	




In	 1953	 there	 was	 a	 significant	 breakthrough	 made	 by	 Dr	 Paul	 di	 Sant’Agnese,	 who	
revealed	the	phenomenon	of	salt	loss	in	the	sweat	of	patients	with	CF.	He	discovered	this	
during	the	heat	wave	of	New	York	in	1948,	where	he	found	that	his	CF	patients	became	
especially	 salt-depleted	 (7).	 Thereafter,	 tasting	 the	 sweat	 of	 patients	 was	 no	 longer	




did	 CF	 research.	 Due	 to	 the	 expansion	 of	 CF	 care,	 a	 patient	 registry	 was	 launched	 to	
gather	information	about	CF	patients	(8).	
The	cause	of	CF	became	an	important	focus.	In	1989	a	group	of	scientists	discovered	the	
most	 common	 genetic	 mutation	 causing	 CF	 to	 be	 “a	 loss	 of	 phenylalanine	 residue	 at	
amino	acid	position	508”;	they	also	discovered	the	defective	protein	associated	with	the	
gene,	 CFTR	 (9).	 This	 critical	 finding	 enabled	 scientists	 to	 understand	 more	 about	 the	
aetiology	of	CF	and	paved	the	way	for	the	development	of	CF-specific	drugs	in	the	1990s.	











	Although	 it	 is	 a	 recessive	 condition,	 CF	 is	 still	 the	 commonest,	 life-limiting,	 genetically	
inherited	 disease	 found	 in	 white	 populations	 (11).	 Approximately	 1	 in	 25	 of	 the	 UK	





and	 predominantly	 affects	 the	 white	 population;	 over	 90%	 of	 individuals	 with	 CF	 are	
white.	(8)	




children	 are	 progressing	 to	 adulthood.	 Children	 are	 usually	 diagnosed	 in	 one	 of	 three	
ways:	at	birth	with	meconium	ileus,	detection	through	newborn	screening	or	presenting	
with	 failure	 to	 thrive	and/or	 chronic	 infections.	 The	number	of	 children	has	most	 likely	
remained	 stable	 because	 newborn	 screening	 (described	 in	 more	 detail	 in	 2.7.2)	 has	






















to	 nonsense	 mutations,	 frame-shift	 mutations	 and	 deletions.	 This	 results	 in	 an	






taken	 to	 the	 cell	 surface.	 These	 defects	 are	 caused	 by	missense	mutations	 and	
deletions.	The	most	common	mutation,	Phe508del,	falls	into	this	class.	It	accounts	




mutations	 that	 alter	 the	 chloride	 channel	 itself,	 interrupting	 channel	 regulation	
and	 function.	 They	 result	 in	 reduced	 or	 no	 channel	 opening.	 Examples	 include	
G551D,	G551S	and	G1349D.	
4. Class	 IV	 mutations	 are	 usually	 missense	 mutations	 that	 affect	 the	 structure	
chloride	channel	pore,	hence	 reducing	 the	anion	conductance.	Examples	 include	
R117H,	R334W	and	R347P.	
5. Class	 V	 mutations	 are	 also	 missense	 mutations	 caused	 by	 a	 defect	 in	 the	 pre-
MRNA	 splicing	 of	 the	 nascent	 protein.	 Consequently,	 there	 will	 be	 reduced	
synthesis	of	the	protein,	providing	less	CFTR	protein	at	the	cell	surface.	Examples	
include	2789+5G>A	and	A455E.		
6. There	 is	also	a	sixth	class	of	CFTR	mutation,	which	 increases	the	turnover	of	 the	
CFTR	 protein	 at	 the	 cell	 surface,	 reducing	 its	 stability	 (14,17).	 However	 this	
mutation	has	not	been	as	 thoroughly	 investigated	as	 the	other	 five	defects	 (18)	







In	 addition	 to	 assigning	 the	 mutations	 to	 the	 effect	 they	 have	 on	 a	 cellular	 level,	 CF	
mutations	can	also	be	categorised	according	 to	 their	 clinical	 consequences.	Historically,	
the	 two	 categories	 were	 “classic”	 CF	 and	 “non-classic”	 CF,	 with	 “classic”	 CF	 describing	
those	 patients	with	multi-organ	 disease.	However,	 this	 distinction	 is	 not	 very	 useful	 in	
practice,	which	is	why	it	is	no	longer	used	(18).	Children	within	one	family	with	the	same	
genotype	 can	 present	with	 different	 clinical	 features.	 There	 are	 areas	 in	 CF	where	 the	
genotype-phenotype	 relationship	 is	 strong,	 such	 as	 in	 pancreatic	 sufficiency	 status.	
However,	 for	 characteristics	 such	 as	 pulmonary	 function,	 or	 whether	 a	 patient	 will	
develop	diabetes,	genotype	does	not	usually	predict	phenotype.			
There	are	many	factors	(other	than	the	type	of	CFTR	mutation)	contributing	to	the	health	
















The	 pathophysiology	 of	 CF	 lung	 disease	 is	 very	 complex	 and	 not	 fully	 understood.	 CF	
produces	 a	 cycle	 of	 inflammation	 and	 infection	 leading	 to	 lasting	 airway	 damage,	 but	
there	 is	 still	 debate	 as	 to	 how	 this	 occurs	 (23)	 and	whether	 inflammation	 or	 infection	
comes	 first.	 Poor	 bacterial	 elimination	 is	 thought	 to	 play	 an	 important	 role	 in	 the	
inflammatory	 response	 in	 CF	 lungs	 and	 there	 have	 been	 3	main	 hypotheses	 that	 have	





found	 that,	 in	 both	 normal	 and	 CF	 patients,	 the	 airway	 surface	 liquid	 (ASL)	 is	 actually	
isotonic,	rather	than	hypertonic	(26).	
The	 second	 theory,	 the	 “low	 volume”	 hypothesis,	 suggests	 that	 the	 defective	 chloride	
channels	prevents	an	osmotic	gradient	occurring,	so	there	will	be	very	little	water	moving	
out	 of	 the	 epithelial	 cells.	 As	 such,	 the	 epithelial	 surface	 becomes	 dehydrated	 and	 the	
airway	 surface	 liquid	 (ASL)	 will	 be	 viscous	 and	 sticky.	 This	 results	 in	 an	 ineffective	
mucociliary	 clearance	 and	 hence	 higher	 susceptibility	 to	 infection	 (24).	 In	 vitro	 studies	















about	 the	 course	 of	 CF	 lung	 disease.	 At	 birth,	 the	 pigs’	 lungs	 did	 not	 show	 signs	 of	
inflammation,	 much	 like	 humans	 with	 CF.	 However,	 after	 an	 intrapulmonary	 bacterial	
challenge,	the	CF	pigs	could	not	eliminate	the	pathogens	as	the	healthy	pigs	could.	This	
signified	that	the	pig	model	also	supported	the	theory	that	it	is	poor	bacterial	elimination	




When	 the	 inflammatory	 response	 occurs,	 there	 is	 a	 high	 production	 of	 inflammatory	
mediators	 such	 as	 interleukin-8	 (IL-8).	 IL-8	 attracts	 vast	 numbers	 of	 neutrophils	 to	 the	
lungs,	 which	 produce	 enzymes	 such	 as	 oxidases	 and	 proteases.	 The	 neutrophils	 are	
thought	 to	be	 the	main	cause	of	pathology	 in	CF	 lung	disease,	but	 the	 loss	of	 immune-
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regulatory	mediators	such	as	 IL-10	are	also	thought	to	play	a	part	 (31).	Chronically,	 this	
cycle	of	infection	and	inflammation	causes	lasting	damage	to	the	structure	of	the	airways.		
The	broncho-alveolar	lavage	(BAL)	results	from	CF	pig	models	showed	changes	consistent	










and	 show	 that	 the	 inflammation/infection	debate	 is	 far	 from	settled.	 The	CF	pig	model	
has	 provided	 some	 valuable	 insight	 into	 the	 pathogenesis	 of	 CF	 and	 has	 shown	 the	
consequences	 of	 spontaneous	 and	 chronic	 infections	 in	 CF	 lung	disease.	 But	 of	 course,	
there	are	 limitations	 to	animal	models.	We	cannot	 replicate	CF	 in	other	animals	 just	as	













pancreas	was	 found,	 as	well	 as	distended	pancreatic	ducts	 and	 fibrosis	 (23).	 Pancreatic	










The	 gold-standard	 diagnostic	 test	 for	 CF	 is	 the	 sweat	 test,	 in	 which	 the	 chloride	
concentration	 of	 the	 gland	 is	 measured.	 Pilocarpine	 is	 deposited	 onto	 the	 skin	 by	







symptomatic,	 the	 test	 can	be	performed	48	hours	after	birth	–	 if	enough	sweat	 can	be	
collected.	This	can	often	be	difficult,	as	the	minimum	volume	of	sweat	required	for	a	valid	
result	should	exceed	1	g/m2	per	minute	(39).	
If	 the	 test	 reveals	 sweat	 chloride	 values	 of	≥60mmol/L,	 it	 is	 considered	 abnormal	 and	
indicative	 of	 CF.	 Values	 between	 40	 and	 59mmol/L	 are	 intermediate	 and	 values	 below	
39mmol/L	are	considered	normal.	However,	in	infants	under	6	months	of	age,	the	values	
are	 slightly	 different.	 Results	 ≥60mmol/l	 are	 still	 considered	 abnormal,	 but	 the	
intermediate	range	is	30-59	mmol/l	and	≤29mmol/l	means	CF	is	unlikely	(37).		
As	 with	 most	 diagnostic	 tests,	 there	 are	 some	 pitfalls	 when	 relying	 on	 the	 sweat	 test	
result.	 Many	 CF	 patients	 have	 elevated	 sweat	 chloride	 concentrations,	 but	 some	
mutations,	e.g.	R711H,	are	associated	with	borderline	or	even	normal	test	results	(40).	A	
CF	 diagnosis	may	 take	 several	 years	 in	 these	 patients,	 during	which	 time	 the	 child	 can	
develop	chest	symptoms	consistent	with	CF.		
Furthermore,	 the	 practicalities	 of	 performing	 a	 sweat	 test	 can	 be	 demanding,	 so	 user	
error	and	false	results	can	occur.	False	positives	may	also	occur	in	rare	conditions	such	as	




Before	a	diagnostic	 test	 is	used,	all	newborns	 in	 the	UK	are	screened	using	 the	Guthrie	
heel	 prick,	 or	 blood	 spot	 test,	 in	 which	 a	 raised	 immune-reactive	 trypsinogen	 (IRT)	 is	
considered	to	be	abnormal.	The	screening	has	been	available	for	all	newborns	in	the	UK	
since	 2007	 (41).	 Newborn	 screening	 has	 some	 key	 advantages.	 Firstly,	 it	 will	 lead	 to	 a	
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or	 normal	 (in	 the	 presence	 of	 2	mutations,	 one	 if	 which	 is	 unclear).	 This	 is	 called	 “CF	
screen-	positive,	inconclusive	diagnosis”	or	“CFSPID”.	Infants	with	this	diagnosis	are	often	
asymptomatic	but	 can	develop	mild	CF-related	 symptoms	as	 they	 grow	up.	 “CFSPID”	 is	
given	as	a	diagnostic	 label	 to	provide	an	explanation	 for	 families	 regarding	 their	 child’s	
condition	and	to	activate	appropriate	support	in	healthcare	settings	(44).	
	
After	 a	 raised	 IRT,	 further	 screening	 in	 the	 form	 of	 DNA	 testing	 can	 be	 carried	 out	 to	
determine	 the	 genotype	of	 the	 individual.	DNA	 testing	 can	 also	be	used	 for	 individuals	
with	an	intermediate	chloride	value	to	help	ascertain	the	diagnosis	(37).	Once	a	diagnosis	
has	 been	 made,	 the	 individual’s	 relatives	 may	 be	 offered	 screening;	 the	 siblings	 are	






To	determine	pancreatic	sufficiency	status,	 the	faecal	elastase-1	enzyme	 is	measured	 in	
the	individual’s	stool.	This	test	is	non-invasive	and	easy	to	perform,	as	well	as	being	more	
sensitive	and	specific	than	direct	pancreatic	stimulation	tests	(45).	This	is	because	there	is	







There	 is	 a	 definite	 multi-disciplinary	 approach	 in	 the	 management	 of	 CF.	 The	 team	 is	
comprised	 of	 doctors,	 pharmacists,	 physiotherapists,	 dieticians,	 psychologists,	 social	
workers,	nurses	and	research	coordinators.	Such	a	large	team	is	required	because	CF	is	a	
















Infants	 develop	 recurrent	 respiratory	 symptoms	 such	 as	 a	 cough,	 wheeze,	 dyspnoea,	
episodes	of	bronchiolitis	and	pneumonias.	Nose	polyps	and	sinusitis	may	also	occur	(11).	
The	 cough	 itself	may	 initially	 present	 as	 a	 recurrent,	 dry	 one	 that	will	 usually	 go	on	 to	
produce	 mucus	 and,	 eventually,	 purulent	 sputum	 (47).	 As	 the	 disease	 progresses,	 the	
build	up	of	 thick,	viscid	mucus	 in	 the	 lungs	 leads	 to	 recurrent	chest	 infections	 involving	
specific	bacteria	and	the	 individual	can	become	chronically	 infected.	The	most	common	
bacteria	 are	 Staphylococcus	 aureus,	 Haemophilus	 influenzae	 and,	 ultimately,	
Pseudomonas	 aeruginosa	 and	 Burkholderia	 species.	 Chronic	 infections	 with	 these	
bacteria	may	cause	bronchial	wall	damage,	bronchiectasis	and	abscess	formation	(16).		P.	
aeruginosa	 is	 often	 found	 in	 adults	with	 CF	 as	 it	 can	 be	 difficult	 to	 eradicate	 once	 the	
bacteria	is	deep	within	the	lung	tissue.		A	complication	that	can	occur	with	B.	Cepacia	 is	
“Cepacia	syndrome”,	which	is	a	combination	of	bacteraemia	and	necrotising	pneumonia.	
It	 produces	 bilateral	 nodular	 consolidation	 and	 cavitation	 and	 can	 result	 in	 respiratory	
failure	(48).	
In	well-established	disease,	there	are	certain	signs	to	observe	during	examination.	Finger	
clubbing	 may	 suggest	 advanced	 lung	 disease	 (although	 it	 not	 an	 accurate	 marker	 of	




Other	 complications	 of	 CF	 include	 pneumothorax,	 lobar	 collapse,	 pulmonary	
hypertension,	(due	to	chronic	hypoxia)	Aspergillus-	related	lung	disease	and	haemoptysis.		










Patients	 are	 separated	 according	 to	 their	 bacterial-colonisation;	 for	 example,	
Pseudomonas-infected	 patients	 are	 grouped	 together	 in	 one	 clinic	 to	 prevent	 the	
infection	of	non-colonised	patients.	At	every	appointment,	the	clinician	should	conduct	a	
history	 and	 respiratory	 examination	 to	 determine	 the	 patient’s	 respiratory	 signs	 and	
symptoms	 (or	 lack	 thereof).	 The	 physiotherapist	 should	 also	 assess	 the	 quality	 of	 the	
patient’s	 airway	 clearance	 techniques	 (see	 below)	 and	 ensure	 that	 they	 have	 a	 regular	
physiotherapy	routine.			
Pulmonary	 function	 tests	are	conducted	every	appointment	 to	monitor	 the	FEV1%.	The	
patient’s	oxyhaemoglobin	saturation	is	also	noted	and	a	sputum	sample	is	taken	(47).	On	







Airway	 clearance	 is	 a	 key	 component	 of	 CF	management,	 so	 various	 physical	 therapies	
are	utilised	in	the	treatment	of	CF.	These	are	comprised	of	the	different	airway	clearance	
regimens	 and	 physical	 training.	 Examples	 of	 airway	 clearance	 techniques	 include	
Conventional	Chest	Physiotherapy	(CCPT),	Positive	Expiratory	Pressure	(PEP),	Active	Cycle	
of	 Breathing	 Techniques	 (ACBT),	 Autogenic	 Drainage	 (AD),	 mechanical	 percussion	 and	
High-Frequency	 Chest	 Compression	 (HFCC).	 The	 general	 consensus	 among	 healthcare	
professionals	 is	 that	 airway	 clearance	 techniques	 encourage	 muco-ciliary	 clearance	 by	
altering	airflow	and	mucous	viscosity.	Furthermore,	short	 -term	trials	demonstrated	the	
benefit	 of	 airway	 clearance	 techniques	 compared	 no	 airway	 clearance	 techniques.	
However,	the	comparative	efficacy	of	individual	airway	clearance	techniques	seems	to	be	
a	subject	needing	further	research,	as	there	is	limited	evidence	on	this	at	present.	




for	 infective	 exacerbations.	 Individuals	 with	 CF	 are	 more	 susceptible	 to	 infection	 with	
organisms	 such	 as	 P.	 Aeruginosa,	 Aspergillus,	 B.	 Cepacia	 and	 Methicillin-resistant	
Staphylococcus	 aureus	 (MRSA).	 If	 chronically	 infected,	 these	 organisms	 can	 have	 a	
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treated	 with	 intravenous	 antibiotics.	 The	 choice	 of	 antibiotic	 is	 dependent	 on	 the	






In	 terms	 of	 prophylaxis,	 all	 patients	 who	 are	 chronically	 infected	 with	 P.	 aeruginosa	
should	be	given	long-term,	nebulised	anti-pseudomonal	therapy.	Furthermore,	for	infants	




twice	daily	 can	 slow	 the	progression	of	mild	 to	moderate	 lung	disease	 in	CF.	However,	




and	 medications	 are	 required	 to	 shift	 these	 secretions.	 The	 most	 commonly	 used	
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mucolytics	 are	 Human	 recombinant	 DNase	 (Dornase	 alfa)	 and	 Hypertonic	 saline,	 both	
administered	via	a	nebuliser.	Dornase	alfa	works	by	degrading	the	DNA	within	CF	mucus,	
thereby	decreasing	 its	 viscosity.	Hypertonic	 Saline	works	by	osmosis,	 drawing	 fluid	 into	
the	 lumen	of	 the	airway,	 increasing	the	hydration	of	 the	airway	surface	 liquid	 (53).	 In	a	
controlled	 trial,	 hypertonic	 saline	 was	 shown	 to	 decrease	 the	 overall	 number	 of	
exacerbations	 and	 antibiotic	 use	 for	 exacerbations;	 although	 there	 was	 no	 significant	
effect	 on	 the	 rate	 of	 change	 in	 lung	 function,	 hypertonic	 saline	was	 associated	with	 a	
moderate,	sustained	improvement	in	the	level	of	lung	function	(54).	
Chronic	 use	 of	 Dornase	 alfa	 and	 Hypertonic	 Saline	 are	 therefore	 recommended	 for	 CF	
patients	who	are	6	years	and	older	 to	 improve	 lung	 function	and	 reduce	exacerbations	
(51).	
Other	 mucolytics	 are	 N-acetylcysteine	 (NAC)	 and	 mannitol.	 N-acetylcysteine	 works	 by	
breaking	 disulphide	 bonds	 in	 mucus,	 which	 decreases	 its	 viscosity.	 However,	 the	 CF	
foundation	does	not	recommend	NAC	for	chronic	use,	due	to	lack	of	sufficient	evidence	
on	 the	 subject.	On	 the	other	hand,	 inhaled,	 dry	powder	 (mannitol)	 has	been	 shown	 to	




Lung	 transplantation	 is	 reserved	 for	 end-stage	 CF	 for	 those	 patients	 who	 are	 not	
responding	to	medical	therapy,	to	the	extent	where	the	individual	is	hypercapnic	and/or	
needing	supplemental	oxygen.	As	with	all	 transplants,	 there	are	some	contraindications	
to	 lung	 transplantation.	 Sepsis,	 multi-organ	 dysfunction	 and	 colonisation	 with	
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Burkholderia	 Cepacia	 are	 among	 the	 absolute	 contraindications,	 but	 other	 factors	 are	







16	and	over,	 compared	 to	 those	between	 the	ages	of	10	and	16	 (8).	 This	 is	due	 to	 the	
progressive	 nature	 of	 the	 destruction	 of	 pancreatic	 tissue	 from	 exocrine	 pancreatic	
insufficiency.	 Over	 time,	 fibrosis	 and	 fatty	 infiltration	 destroys	 beta	 islet	 cell	 structure.	
There	 is	 also	 evidence	 from	 mouse	 models	 that	 CFTR	 dysfunction	 itself	 may	 also	






CFRD	 is	 thought	 to	 be	 due	 to	 factors	 such	 as	 anti-inflammatory	 therapy,	 (i.e.	
corticosteroid	 use	 and	 increased	 oxidative	 stress)	 which	 may	 lead	 to	 impaired	
translocation	of	important	glucose	transporters	at	the	cell	surface	(59,	58).	
CFRD	often	presents	 insidiously;	not	all	patients	will	experience	the	classic	symptoms	of	






Patients	with	 pancreatic	 insufficiency	 are	more	 likely	 to	 develop	CFRD,	 so	 the	 CF	 team	
take	measures	to	screen,	monitor	and	manage	patients	who	are	at	risk.		










2.8.6	 Gastrointestinal	 and	 Hepato-biliary	 System	 involvement	
(excluding	constipation	and	DIOS)	
7-10%	neonates	will	present	with	meconium	ileus,	in	which	the	meconium	obstructs	the	
intestine	 and	 signs	 of	 bowel	 obstruction	 are	 observed,	 such	 as	 bilious	 vomiting	 and	













Individuals	 can	also	present	with	acute	pancreatitis.	Viscid	mucous	 in	 the	pancreas	 can	










The	 dietician	 guides	 the	management	 of	 nutritional	 interventions	 in	 CF.	 At	 each	 clinic	





patient	 (or	 parents	 of	 the	 patient)	 on	 foods	 to	 incorporate	 into	 the	 diet.	 Annually,	
patients	have	a	blood	test	to	measure	their	vitamin	A,	D	and	E	 levels	and	a	coagulation	
profile	 to	measure	 their	vitamin	K	 levels.	Due	 to	pancreatic	 insufficiency,	most	patients	
with	 CF	 do	 not	 effectively	 absorb	 fat-soluble	 vitamins	 A,	 D,	 E	 and	 K.	 Therefore,	 these	
vitamins	must	be	given	regularly	based	on	the	patient’s	blood	vitamin	levels	(prothrombin	
time	 is	 used	 to	 measure	 levels	 of	 vitamin	 K)	 and	 based	 on	 CF	 nutritional	
recommendations	(64).	
Pancreatic	 insufficient	 patients	 also	 require	 Pancreatic	 Enzyme	 Replacement	 Therapy	
(PERT).	These	are	given	as	oral	capsules	called	Creon®, made	up	of	 lipase,	amylase	and	
protease,	 which	 should	 be	 taken	 with	 every	 food	 intake.	 In	 babies,	 enzyme	 granules	
called	Creon	Micro®	are	used	instead.	These	are	usually	given	before	feeds	with	a	small	
spoonful	 of	 fruit	 puree.	 The	 fruit	 puree	 prevents	 the	 granules	 from	 degrading	 in	 the	
gastric	acid,	but	also	makes	it	easier	for	the	infant	to	swallow	(64).	




Patients	with	CF	have	much	greater	energy	demands	 than	healthy	 individuals	 (65)	and,	
unfortunately,	 it	 can	 be	 difficult	 to	 always	meet	 those	 demands.	 In	 addition	 to	meals,	



































(DEXA)	scans	 to	monitor	 their	bone	density.	Patients	are	already	recommended	to	 take	




Psychological	 input	 from	 the	 multi-disciplinary	 team	 is	 an	 important	 factor	 in	 the	
management	of	CF	because	many	 individuals	 struggle	 (in	different	ways)	 in	growing	up	


















Furthermore,	 sibling	 relationships	may	 become	problematic	 in	 families	with	 a	 CF	 child.	















than	ever	before.	The	 fact	 that	a	high	calorie,	high	 fat	diet	 is	emphasised	 in	CF	may	be	
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conflicting	 for	 some	 adolescents	 who	 hear	 otherwise	 from	 peers	 or	 online.	 Not	 to	
mention	the	fact	that	their	weight	is	monitored	very	closely	with	measurements	at	every	
appointment.	Although	the	prevalence	of	eating	disorders	 is	no	different	to	the	general	





adolescents	 with	 CF	 (74).	 Some	 studies	 claim	 that	 symptoms	 of	 both	 depression	 and	
anxiety	are	elevated	in	patients	compared	to	the	general	population	(71),	but	others	find	
that	depression	does	not	significantly	affect	patients	with	CF	(72).		




Currently,	 the	median	 life	 expectancy	 for	 someone	with	 CF	 is	 41	 years	 old,	 although	 a	
baby	born	today	could	be	projected	to	have	a	median	 life	expectancy	of	56	years	 if	 the	
mortality	rate	continues	to	decrease	at	the	rate	observed	between	2000	and	2010	(76).		
	The	next	sections	will	explain	the	different	factors	that	may	affect	prognosis,	such	as	the	







class	 II	 (higher	 mortality)	 and	 classes	 IV	 and	 V,	 with	 class	 IV	 possessing	 the	 lowest	





differences	 within	 the	 same	 class	 (77).	 These	 findings	 are	 similar	 to	 the	 differences	 in	
phenotype	 and	 class	 studied	 by	 Boeck	 (19).	 The	 non-Phe508del	 allele	 in	 heterozygotes	
can	also	play	a	part	in	the	relationship	between	mortality	and	phenotype;	as	mentioned	




























in	 CF	 (81).	 A	 1992	 study	 established	 that	 patients	 with	 a	 %FEV1	 <	 30%	 had	 a	 2	 year	
mortality	 over	 50%	 (82).	 Although	 this	 finding	 is	 not	 fully	 reliable	 according	 to	 more	
recent	 studies	 (81),	 it	 still	 illustrates	 the	 significance	 of	 pulmonary	 function	 in	 CF	
prognosis.		
Pancreatic	 insufficiency	 is	 also	 associated	 with	 significant	 decreases	 in	 FEV1%	 and	
patients	with	pancreatic	 insufficiency	are	 twice	as	 likely	 to	develop	 severe	 lung	disease	
(%FEV1<40%	 predicted)	 (80,	 83).	 Pancreatic	 insufficiency	 is	 also	 related	 to	 fat	
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malabsorption	 and	 therefore	 poor	 nutrition,	which	 is	 a	 risk	 factor	 for	 poor	 outcome	 in	
itself.		
Another	 predicator	 or	 poor	 outcome	 is	 CFRD,	 which	 is	 associated	 with	 insufficient	
nutritional	outcomes	and	more	 severe	 lung	disease	 -	both	predictors	of	poor	prognosis	
(80).	Liver	disease	is	also	a	serious	morbidity	of	CF	as	it	is	the	third	highest	cause	of	death	
after	respiratory	failure	and	transplant	complications	(83).		
Overall	nutritional	 status	of	 the	 individual	affects	prognosis,	as	demonstrated	 in	a	2006	
study	looking	at	risk	factors	for	death	amongst	CF	patients	awaiting	lung	transplantation.	
They	 found	 that	 those	 requiring	 nutritional	 intervention	 had	 a	 higher	 risk	 of	 death	
compared	to	their	counterparts	(84).		
CF	 complications	are	 related	 to	one	another	and	 it	 is	 important	 to	appreciate	 that	one	
complication	 may	 lead	 to	 or	 worsen	 others.	 	 For	 example,	 respiratory	 complications,	
CFRD,	gastrointestinal	and	hepato-biliary	complications	all	affect	the	nutritional	status	of	
the	patient.	If	the	patient’s	nutritional	status	is	poor,	they	will	be	less	mobile,	have	lower	
energy	 levels	 and	mood,	 which	may	 affect	 their	 adherence	 to	 treatment.	 The	 cycle	 of	




In	 the	previous	 section	 I	discussed	 the	current	MDT	management	of	CF.	There	has	also	







small	 molecule	 therapies.	 One	 of	 the	 most	 successful	 of	 these	 is	 the	 drug,	 Ivacaftor.	
Unlike	 other	 CF	medications,	 Ivacaftor	 works	 by	 targeting	 CFTR	 itself,	 potentiating	 the	
action	of	channel	opening	so	that	chloride	ions	can	pass	through.	Ivacaftor	has	proven	to	




azithromycin	and	 inhaled	 tobramycin)	 the	change	 in	%FEV1	was	even	greater,	at	17.2%	
improvement	 compared	 to	 the	placebo.	This	was	also	 sustained	 for	48	weeks.	At	week	
48,	67%	patients	in	the	Ivacaftor	group	(compared	to	41%	in	the	placebo)	were	also	free	
from	pulmonary	exacerbations	(85).	This	treatment	is	currently	licensed	for	all	patients	(2	
years	 and	 above)	 with	 the	 G551D	 mutation	 (10).	 	 Unfortunately,	 Ivacaftor	 is	 a	 very	
expensive	treatment.	In	the	UK,	the	cost	stands	at	£182,000	per	patient	per	year.	This	had	
led	 to	more	 rigid	 testing	of	 the	 clinical	 benefit	 of	 Ivacaftor,	which	may	 limit	 its	 use	 for	
other	mutations	(86).	
	
Ivacaftor	was	 also	 tested	 for	 the	most	 common	mutation,	 homozygous	 Phe508del,	 but	
was	 shown	 to	have	very	 limited	efficacy	 (86).	The	overall	 adverse	effect	 frequency	was	
similar	 to	 the	 placebo	 group	 (87.5%	 in	 the	 ivacaftor	 group	 and	 89.3%	 in	 the	 placebo	





Following	 on	 from	 the	 research	 on	 Ivacaftor,	 another	 small	 molecule	 therapy	 was	
produced:	Lumacaftor.	Lumacaftor	was	originally	created	for	the	homozygous	Phe508del	




does	 not	 currently	 recommend	 it	 for	 CF.	 Although	 the	 improvement	 in	 %FEV1	 was	
significant,	 it	was	relatively	modest,	ranging	from	4.3	to	6.7%	compared	to	the	placebo.	







of	 which	 the	 results	 were	 encouraging,	 but	 not	 yet	 suitable	 for	 clinical	 care.	 It	 was	
encouraging	 that	 there	 was	 a	 small	 but	 statistically	 significant	 improvement	 in	 %FEV1	
with	the	pGM169/GL67A	gene	therapy	formulation.	However,	this	was	mainly	driven	by	a	
fall	 in	 the	%FEV1	 in	 the	 placebo	 group	 (90).	 The	 same	 organisation	 is	 also	 planning	 to	
conduct	a	clinical	trial	in	2017	using	a	Lentiviral	vector	gene	therapy.	So	far,	they	have	not	












DIOS	 is	 a	 gastrointestinal	 complication	 of	 CF.	 It	 is	 distinct	 from	 constipation	 (another	
complication	in	CF)	in	its	pathophysiology,	although	the	two	are	often	confused	with	one	






















































The	 Rome	 III	 criteria	 are	 generally	 used	 to	 diagnose	 constipation.	 A	 patient	must	 have	
experienced	 at	 least	 2	 of	 the	 following	 symptoms	 in	 the	 past	 3	months:	 fewer	 than	 3	
bowel	 movements	 per	 week,	 straining,	 lumpy	 or	 hard	 stools,	 sensation	 of	 anorectal	
obstruction,	 sensation	 of	 incomplete	 defection	 and	 manual	 manoeuvring	 required	 to	
defecate	(92).	
Sometimes	 it	 can	 be	 difficult	 to	 differentiate	 between	 incomplete	 DIOS	 and	 severe	
constipation	 in	 clinical	 practice	 and	 they	may	 both	 present	with	 abdominal	 pain	 and	 a	























picture.	 A	 plain	 abdominal	 radiograph	 is	 typically	 used,	 which	 shows	 faecal	 loading	
throughout	 the	 colon	 (91).	 However,	 it	 is	 worth	 noting	 that	 in	 clinical	 practice,	
constipation	 can	 usually	 be	 diagnosed	 with	 a	 detailed	 history,	 abdominal	 and	 rectal	











are	 adequately	 hydrated	 and	 on	 a	 balanced	 diet	 with	 good	 fibre	 intake.	 First-line	
treatment	for	constipation	is	commonly	an	osmotic	laxative,	such	as	polyethylene	glycol	
3350,	 under	 the	 brand	 name	 Movicol®;	 this	 should	 be	 given	 on	 an	 escalating	 dose	




patient	may	be	given	up	 to	8	sachets	on	 the	 first	day,	after	which	 the	dose	 is	 reduced.	
There	is	also	Paediatric	Movicol®	which	is	administered	at	a	dose	of	1	sachet	per	day	for	
children	aged	2	to	5	years	and	2	sachets	per	day	for	children	aged	6	to	11	years.		Another	





resolve	 within	 2	 weeks,	 a	 stimulant	 laxative	 can	 also	 be	 added	 or	 substituted	 if	 the	
osmotic	 laxative	 is	 not	 tolerated;	 for	 example,	 senna,	 sodium	 picosulphate	 or	 sodium	






20mg	once	daily,	which	 is	adjusted	according	 to	 the	response.	Sodium	docusate	can	be	













A	very	popular	 treatment	of	MIE	 in	 the	1960s	and	70s	was	oral	n-acetylcysteine	 (NAC),	
also	used	to	treat	meconium	ileus	in	neonates.	The	first	documented	use	of	this	in	post-
neonatal	meconium	ileus	was	in	1967	(106).	Another	drug	used	to	successfully	treat	acute	
MIE,	 first	 described	 in	 a	 1986	 study,	 was	 diatrizoate	 maglumine	(Gastrografin®)	 (107).	
Both	NAC	and	diatrizoate	are	still	used	to	treat	DIOS	in	many	centres	today.	
The	use	of	pancreatic	enzymes	(e.g.	pancreatin),	mucolytics	(e.g.	NAC)	and	enemas	were	
deemed	unhelpful	 for	 the	treatment	of	MIE	 in	a	1986	Lancet	article,	 just	after	MIE	was	
given	 the	 name	DIOS.	 The	 article	 described	 them	as	 “neither	 predictably	 effective,	 nor	
rapid	in	action”	(108).	There	are	quite	a	few	contradictions	in	historical	literature	on	the	
subject	of	DIOS	 treatments.	A	proportion	 is	made	up	of	case	studies.	One	should	 judge	






higher	 figures	 for	 incomplete	 DIOS	 (102).	 The	 CF	 annual	 report	 shows	 an	 increase	 in	
intestinal	obstruction	 for	adults	with	CF	 (7.4%)	compared	 to	 those	under	 the	age	of	16	
(3%)	(8).	However,	there	appear	to	be	disparities	in	the	literature	because	in	2016	Munck	
found	similar	 incidences	of	DIOS	between	children	and	adults	 (111).	The	reason	for	this	





is	 anecdotally	 more	 common	 in	 those	 who	 do	 not	 adhere	 to	 pancreatic	 enzyme	

































There	 is	 also	 evidence	 of	 abnormalities	 in	 bile	 acid	 physiology	 in	 CF.	 Bile	 acids	 usually	








for	 the	 digestive	 function	 of	 pancreatic	 enzymes	 and	 bile	 salts,	 contributing	 to	 the	
relatively	 poor	 digestive	 function	 of	 the	 small	 intestine	 in	 CF	 (116).	 Furthermore,	 the	
bicarbonate	is	said	to	help	maintain	the	normal	solubility	of	intestinal	mucus,	so	it	follows	



















In	 summary,	 there	are	various	mechanisms	 involved	 in	 the	pathogenesis	of	DIOS,	 some	









abdominal	 pain,	 distension	 and	 vomiting	 (122).	 If	 the	 individual	 presents	 more	
intermittently	-	with	episodes	of	abdominal	pain,	nausea	or	anorexia	without	vomiting	-	
the	 diagnosis	 is	 more	 likely	 to	 be	 incomplete	 DIOS	 (91).	 To	 differentiate	 between	
constipation	 and	 incomplete	 DIOS	 can	 be	 tricky,	 but	 there	 are	 some	 important	







abdominal	 palpation	 and	 the	 patient	may	 experience	 a	 colicky,	 progressive	 pain	 in	 the	















































If	 a	 diagnosis	 of	 incomplete	DIOS	 is	made	 but	 the	 patient	 is	 clinically	 stable,	 they	may	
respond	to	one	of	the	laxative	regimens	described	in	section	2.14.2.	However,	if	there	is	














degrade	 the	obstructing	 faecal	material	 (91).	 This	 is	 given	at	 a	dose	of	4	 to	6g	 in	older	





management	 for	 bowel	 obstruction:	 IV	 rehydration,	 nil	 by	 mouth	 and	 nasogastric	
aspiration.	 Diatriozate	 can	 be	 administered	 via	 enema,	 but	 should	 be	 done	 so	 with	
caution	as	fluid	shifts	in	the	bowel	can	lead	to	shock	and	perforation	(125,	91)	The	aim	of	
managing	 complete	DIOS	 is	 to	 avoid	 surgical	 intervention	as	much	as	possible,	 but	 this	
may	be	necessary	if	the	patient	is	not	responding	to	medical	treatment.	
b)	Prevention	of	DIOS	
For	 the	 prevention	 of	 DIOS,	 it	 is	 recommended	 that	 patients	 have	 adequate	 hydration	
and	 good	 adherence	 to	 pancreatic	 enzyme	 therapy.	 Furthermore,	 prophylactic	 laxative	
therapy	is	advised	if	the	patient	has	had	a	previous	episode	of	complete	DIOS	or	clinical	
evidence	of	 incomplete	DIOS.	 It	may	also	be	used	post-operatively	 for	CF	patients	who	
have	undergone	organ	transplantation.	Prophylaxis	can	also	be	given	to	patients	who	are	





DIOS	 has	 been	 discussed	 in	 detail	 in	 this	 section.	 It	 occurs	 when	 thick,	 sticky	 mucus	
produced	 in	 the	 CF	 intestine	 combines	with	 viscid	 faecal	material	 in	 the	 lumen	 of	 the	
terminal	ileum	and/or	caecum.	It	is	distinct	from	constipation	in	its	pathophysiology,	but	
can	 sometimes	 be	 difficult	 to	 distinguish	 clinically.	 However,	 the	 ESPGHAN	CF	Working	




Aside	 from	 measures	 such	 as	 good	 adherence	 to	 pancreatic	 enzyme	 therapy	 and	
adequate	hydration,	 there	 is	 little	 evidence	 for	 any	particular	 laxative	 regimen.	 For	 the	
prevention	 and	 treatment	 of	 DIOS,	 there	 are	many	 different	 types	 of	 laxatives	 used	 in	
various	combinations	across	the	CF	centres	in	the	UK.	This	subject	has	not	been	studied	in	
detail	 and	 as	 such,	 there	 are	 no	 recommendations	 on	 the	 prevention	 or	 treatment	 of	

































the	 results	 of	 the	 consultant	 survey	 (see	 chapter	 5),	 there	 is	much	 variation	 in	 clinical	
practice.		
There	are	some	general	guidelines	about	the	prevention	and	treatment	of	DIOS,	although	
they	 do	 not	 have	 a	 high	 quality	 evidence	 base.	 For	 preventative	 measures,	 adequate	
hydration	and	good	adherence	to	pancreatic	enzyme	supplementation	is	recommended,	
as	well	as	prophylactic	laxative	therapy	for	patients	who	have	had	a	previous	episode	of	
complete	 DIOS.	 Maintenance	 laxative	 therapy	 may	 also	 be	 given	 to	 patients	 with	
incomplete	DIOS	 or	 for	 those	with	 clinical	 or	 radiological	 evidence	 of	 constipation	 (see	
section	2.14.2)	 (91).	 For	 the	 treatment	of	DIOS,	 various	 laxative	 regimens	 can	be	used,	
but	 there	are	no	absolute	 recommendations.	 In	 some	cases,	medical	management	may	
fail	 and	 the	 patients	 will	 have	 to	 undergo	 surgery.	 This	 is	 seen	 as	 a	 last	 resort,	 as	 it	
dramatically	 increases	 the	 risk	 to	 the	patient	 (128).	By	 conducting	Cochrane	 reviews	 to	
investigate	the	current	management	strategies	for	DIOS,	I	aim	to	determine	the	aperients	
that	 are	 supported	 by	 the	 best	 evidence	 and	 secondly,	 identify	 important	 gaps	 in	 the	
research.	By	alerting	clinicians	to	gaps	in	the	literature,	it	may	encourage	further	research	
on	the	topic.		
It	 is	 also	 important	 to	 note	 that	 individuals	with	 CF	 experience	 a	 significant	 treatment	







a	 scaffold	 for	 the	 review	 and	 includes	 the	 essential	 information	 on	 which	 to	 base	 the	
review.	 Sections	 of	 the	 protocol	 include	 the	 background,	 objectives	 and	methods.	 The	
background	section	describes	the	condition	and	intervention,	how	the	intervention	might	
work	and	why	 it	 is	 important	 to	do	 the	 review.	The	objectives	 section	should	 include	a	
primary	 question	 or	 outcome.	 The	 methods	 section	 outlines	 the	 selection	 criteria	 for	
studies,	 search	 strategies	 and	 overview	of	 the	 process	 for	 data	 collection	 and	 analysis.	
The	 protocol	 should	 be	 set	 out	 clearly,	 according	 to	 the	 guidelines	 in	 the	 Cochrane	
handbook	 (129).	 It	 should	 also	 be	 relatively	 easy	 to	 read	 so	 that	 non-experts	 can	
understand	it.		
There	 are	 a	 few	 reasons	 why	 authors	 must	 produce	 a	 protocol.	 Firstly,	 discussing	
strategies	prior	 to	 the	 review	promotes	 transparency	and	 reduces	 risk	of	bias	 from	 the	
authors.	 For	 example,	 by	 setting	 the	 criteria	 for	 inclusion	 of	 studies	 in	 the	 protocol,	 it	
reduces	 the	risk	of	 inclusion	of	studies	 that	are	not	suitable	but	may	have	a	 favourable	
outcome	that	support	the	authors’	hypothesis.	A	protocol	also	ensures	that	peer	review	









































































































































































































































































































































































i)	 Condition	 of	 interest:	 The	 condition	 was	 CF.	 I	 also	 searched	 other	 terms	 for	 cystic	
fibrosis	in	order	to	retrieve	a	higher	number	of	studies.	I	also	included	the	abbreviation	of	
cystic	 fibrosis,	 “CF”,	 as	 well	 as	 “mucoviscidosis”	 and	 “fibrocystic”.	 The	 latter	 refers	 to	
fibrocystic	disease	of	the	pancreas.	Both	terms	were	used	to	describe	CF	in	the	mid	20th	
century	(7).	
ii.)	 Outcome	 of	 interest:	 The	 main	 outcome	 for	 the	 reviews	 was	 distal	 intestinal	
obstruction	 syndrome.	 I	 also	 searched	 the	 abbreviation,	 “DIOS”,	 as	 well	 as	 descriptive	
terms	for	the	condition,	such	as	“faecal	obstruction”	and	“faecal	 impaction”.	 I	searched	
the	 subject	 headings,	 “intestinal	 obstruction”	 and	 “constipation”	 and	 then	 “exploded”	
these	to	include	more	specialised	terms	in	the	search.	I	also	included	the	historical	name	
for	DIOS,	“Meconium	ileus	equivalent”	or	“MIE”	(105)	
iii.)	 Interventions	 of	 interest:	 The	 potential	 interventions	 for	 this	 review	were	 osmotic	
laxatives,	 stimulant	 laxatives,	 mucolytics	 and	 laxatives	 with	 more	 than	 one	 mode	 of	
action.	I	searched	the	index	term,	“Laxatives”	and	exploded	it	to	retrieve	more	definitive	




I	 searched	 thesaurus	 terms	 in	 the	 databases	 that	 had	 an	 indexing	 system	 (CENTRAL,	
MEDLINE	 and	 EMBASE)	 to	 identify	 relevant	 results	 that	 could	 be	 labelled	 as	 different	





I	 also	used	extensive	 truncation	 in	 the	medical	 database	 strategies.	 This	 is	 a	 technique	
used	to	obtain	all	possible	suffix	variations	of	the	word	in	question,	e.g.	“constipate$”	or	
“constipate*”	could	retrieve	terms	such	as	constipated,	constipation	or	constipating.		




narrow	the	results	 in	 the	search	strategy.	This	was	used	at	 the	end	of	each	search.	The	




the	 command,	 “adj”,	 e.g.	 “(faecal	 adj	 (obstruction	 or	 impact*)).	 This	means	 the	 word,	
“faecal”	 should	 appear	 next	 to	 either	 “obstruction”	 or	 “impact*”	 in	 a	 phrase.	 This	
command	 can	 be	 expanded	 to	 include	 words	 that	 appear	 near	 each	 other	 but	 not	





I	 planned	 to	 search	 EMBASE	 using	Ovid	 as	 a	 search	 engine,	 but	 due	 to	 problems	with	
access	to	the	system,	I	had	to	use	Healthcare	Databases	Advanced	Search	(HDAS)	instead.	




























































































































































































































































































































































































































































Of	the	2631	studies	 (after	588	duplicates	were	removed)	 identified	by	 initial	searches,	 I	














The	 study	 was	 a	 randomised,	 double-blind,	 placebo-controlled	 crossover	 trial.	 It	 was	
based	at	a	single	centre	in	Toronto,	Canada.		
The	 duration	 of	 the	 trial	 was	 12	 months.	 The	 participants	 were	 randomised	 into	 two	
groups	to	take	either	the	placebo	or	active	drug	and	then	swapped	to	the	opposite	group	






















The	 active	 drug	 was	 cisapride.	 Participants	 were	 randomised	 into	 two	 groups	 and	
received	(in	a	blind	fashion)	placebo	or	cisapride	for	6	months	each.	They	then	switched	
to	the	other	treatment	arm	for	the	second	6	months	of	the	study.	Patients	between	40	
and	 50kg	 received	 7.5mg	 of	 either	 placebo	 or	 cisapride	 3	 times	 per	 day	 and	 patients	
above	50kg	received	10mg	of	either	placebo	or	cisapride	3	times	per	day.		
The	trial	accounted	for	any	potential	carry-over	treatment	effect	of	the	active	drug.	The	
investigators	did	 this	by	analysing	 the	data	 in	 two	ways.	Measurements	were	 recorded	




The	 radiological	 diagnosis	 of	 DIOS	 was	 measured	 in	 the	 trial	 using	 supine	 abdominal	
radiographs.	 Patients	 were	 interviewed	 for	 adverse	 effects	 and	 also	 reported	 any	
gastrointestinal	and	global	symptoms,	with	the	use	of	scoring	systems.	Other	outcomes	
included	the	number	of	participants	requiring	therapy	for	DIOS	and	stool	weight.	
Irrelevant	 outcomes	 for	 our	 review	 included:	 Anthropometric	measurements	 (e.g.	mid-
arm	 circumference,	 skin	 fold	 thickness),	 frequency	 of	 pulmonary	 infections,	 pulmonary	
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the	 Cochrane	 Review:	 “Interventions	 for	 preventing	 DIOS	 in	 CF”.	 	 The	most	 significant	
outcome	from	this	review	was	that	there	is	a	severe	lack	of	evidence	for	the	prevention	
DIOS	in	CF.	After	carefully	constructing	the	eligibility	criteria	and	outcomes	for	the	review,	
and	 running	 extensive	 searches	 on	 medical	 databases	 and	 registries,	 it	 was	 very	
discouraging	 to	 find	 that	 there	was	a	single	study	 for	 inclusion.	Furthermore,	 this	study	
failed	to	address	any	of	my	primary	outcomes.	It	also	had	an	unclear	risk	of	bias	for	most	





In	 the	 next	 chapter,	 I	 will	 present	 and	 discuss	 the	 findings	 from	 the	 review	 on,	
“Interventions	 for	 the	 treatment	 of	 DIOS”.	 In	 chapter	 6,	 I	 will	 present	 and	 discuss	 the	






































Although	 the	 nature	 of	 the	 intervention	 for	 this	 review	 was	 different	 to	 that	 of	 the	
previous	review	(treatment	versus	prevention	of	DIOS),	many	areas	of	the	PICOS	criteria	
were	the	same	for	both	reviews,	such	as	 the	types	of	participants,	 types	of	studies	and	



















































































































However,	 my	 estimation	 was	 that	 there	 would	 be	 only	 1	 study	 eligible	 for	 inclusion;	
furthermore,	 the	 study	 was	 only	 available	 as	 an	 abstract.	 It	 was	 a	 double-blinded,	
randomized	crossover	trial	(163)	conducted	in	1992	that	investigated	the	use	of	high	and	
low	doses	of	PERT	for	the	treatment	of	DIOS.		The	abstract	indirectly	addressed	one	of	my	
primary	outcomes:	 the	 treatment	 failure	 rate	 (measured	 in	 the	study	as	 the	number	of	
episodes	of	acute	DIOS),	but	did	not	present	the	actual	data	for	this	outcome.	Overall,	the	
abstract	gave	very	little	information	about	PERT	for	the	treatment	of	DIOS.		






to	conduct	a	meta-analysis	 for	 this	 review	and	 therefore	will	not	be	able	 to	 investigate	
the	effectiveness	and	safety	of	various	laxatives	for	the	treatment	of	DIOS.	I	will	draw	my	
conclusions	from	these	results	and	the	results	from	the	previous	review	(the	prevention	
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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
This review aims to evaluate the effectiveness and safety of laxative agents of differing types for preventing DIOS (complete and
incomplete) in children and adults with CF. If possible, we aim to assess the optimal laxative regimen by comparing the evidence for
osmotic laxatives, stimulant laxatives and mucolytic agents.
B A C K G R O U N D
Cystic fibrosis (CF) is an important genetic disorder. It is life-
limiting and affected individuals have dysfunction of several or-
gan systems which results in morbidity and reduced quality of life
(QoL). To be affected a person must possess two faulty copies of
the gene that encodes a protein called the cystic fibrosis transmem-
brane conductance regulator (CFTR). About 1 in 25 of the UK
white population carry a single faulty copy of this gene and one
in 2500 newborns in the UK are born with CF (Tobias 2011).
Worldwide the condition affects approximately 70,000 children
and adults (CF Foundation 2016).
Although respiratory symptoms are prominent, and often the fo-
cus of clinical care, CF is a multifaceted disease which also has
important effects on the gastrointestinal and endocrine systems.
The CFTR is expressed in many cell types throughout the body;
it regulates chloride transport and thus indirectly influences wa-
ter transport across the cell membranes. Absent or dysfunctional
CFTR leads to thickened, dehydrated mucus.
Description of the condition
Intestinal obstruction in CF
Distal intestinal obstruction syndrome (DIOS) is a well-recog-
nised morbidity in CF. It is the result of the accumulation of thick
and sticky material within the bowel (both mucus and faeces) par-
ticularly in the final part of the small intestine (the terminal ileum
and caecum). This mass becomes connected to the bowel wall it-
self and the finger-like projections of the small bowel (intestinal
villi) making it fixed in position and difficult to remove (Colombo
2011). The bowel may be completely blocked (complete DIOS)
or only partially blocked (incomplete DIOS), e.g. when a persis-
1Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
tent mass is found low down on the right-hand side (right iliac
fossa). Previously DIOS was known as meconium ileus equivalent
(MIE), and affects between 10% to 22% of individuals with CF
(Davidson 1987; Dray 2004; Penketh 1987; Rubinstein 1986).
The reported incidence increases with age, with almost 80% of
new cases occurring in adults (Dray 2004). Once an individual
has had DIOS the recurrence risk is about 50% (Dray 2004). A
number of factors contribute to the occurrence of DIOS. It occurs
more commonly in individuals who have pancreatic enzyme defi-
ciency (Munck 2016) and anecdotally is more common in those
who do not adhere to pancreatic enzyme replacement therapy. In
part, it occurs due to the loss of CFTR function in the intestine,
where CFTR regulates chloride, bicarbonate and sodium trans-
port.
Distinguishing DIOS from other causes of bowel
obstruction in CF
The CF gut is prone to obstruction from other causes due to its
altered pathophysiology (van der Doef 2011). A small but sig-
nificant proportion of newborns with CF present either at birth
or shortly afterwards with bowel obstruction - meconium ileus.
Meconium ileus occurs in 13% to 17% of the CF population (van
der Doef 2011). Throughout life, children and adults with CF
are prone to constipation, with almost half of all children studied
(47%) having evidence of constipation (van der Doef 2010). How-
ever, it is possible to distinguish between constipation and DIOS
both clinically and radiologically. One widely-used definition of
DIOS is an acute complete or incomplete faecal obstruction in the
ileocecum; whereas constipation is defined as gradual faecal im-
paction of the total colon (Houwen 2010). Using this definition
in individuals under 18 years of age, 51 episodes of DIOS in 39
individuals were recorded, giving an overall incidence of 6.2 (95%
confidence interval (CI) 4.4 to 7.9) episodes per 1000 patient-
years. Although there is undoubtedly overlap between constipa-
tion and incomplete DIOS, the clinical definition proposed by
Houwen permits the effectiveness of treatments to be monitored
clinically (Houwen 2010).
Description of the intervention
Treatment of constipation and the prevention of complete bowel
obstruction is required as part of optimal care for individuals with
CF. DIOS is predominantly an ileocaecal pathology (Houwen
2010). Many strategies are currently used in clinical practice and
there is a lack of consensus about what the best preventative mea-
sures are likely to be. In addition to ensuring adequate hydration
and adherence with pancreatic enzyme supplementation, different
centres use different combinations of laxatives to prevent DIOS
including lactulose, senna, polyethylene glycol (e.g. Movicol®),
sodium docusate, sodium picosulphate and fibre.
Although most children and adults with CF are prescribed inter-
ventions to prevent DIOS at some stage, there is significant het-
erogeneity observed between clinicians in their choices of agent.
With the advent of newer laxative agents, e.g. Movicol®, some
centres have changed their approach.
This review will focus upon the use of laxative agents (aperients) for
the prevention of DIOS. There are three main groups of laxatives
based upon their primary mechanism of action (although there is
overlap between the mechanism of action for some agents).
1. Osmotic laxatives
Osmotic laxatives are faecal softeners which work by increasing
water in the large bowel, either by drawing fluid from the body
into the bowel or by retaining the fluid they were administered
with.
Lactulose
Lactulose is given orally; it is widely used, but may cause flatulence
or abdominal pain in high doses (Colombo 2011).
Macrogol 3350
Macrogol 3350 is also known as polyethylene glycol, or under
the brand names Movicol®, Laxido® or Klean-Prep®. Movicol®
is recommended as first-line treatment for constipation (NICE
2015). It is commonly given to children for chronic constipation
or at a higher dose in faecal impaction. It can be given as an oral
solution or powder (BNFc 2016). Laxido® is a very similar prod-
uct which is also recommended for treatment of chronic constipa-
tion or impaction. Klean-Prep® can also be used, with the aim to
cleanse the bowel. The solution is given until clear fluid is passed
per rectum. As larger volumes are required, it is often necessary to
administer via gastrostomy or nasogastric tube (Colombo 2011;
NICE 2015).
Diatrizoate
Oral diatrizoate (also known as Gastrografin®) is used by many
centres to treat DIOS. It is given as a single dose, which can be
repeated after 24 hours. Rectal diatrizoate can also be used in more
severe cases (Colombo 2011). As diatrizoate is highly osmotic, the
individual must be adequately hydrated prior to administration in
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Senna acts by stimulating peristalsis and increases the emptying of
the bowel. Senna is therefore useful when the individual has soft
stools, but finds it difficult to pass them (NICE 2015).
Sodium docusate
Sodium docusate acts both as a stimulant and also as a stool soft-
ener. It can be administered orally, but if this does not relieve faecal
impaction, the drug can also be given as an enema (NICE 2015).
Sodium picosulphate
Sodium picosulphate acts by stimulating the mucosa of the large




N-acetylcysteine (also known as Parvolex® ) is indicated for ab-
normal or impaired mucus production. It can be given as a single
oral dose for treatment of meconium ileus or DIOS. It is typically
diluted in a sweet drink, such as orange juice or cola, to mask the
strong and bitter taste (BNFc 2016).
How the intervention might work
Different aperients have different mechanisms of action. Histori-
cally these have been divided into three broad categories as stated
above. In clinical practice it has been helpful to titrate the doses
of these to achieve a reduction in abdominal pains and a nor-
mal physical examination, e.g. resolution of right iliac fossa mass.
Some newer agents (e.g. Movicol®) combine these effects provid-
ing both softening and stimulation.
For preventing DIOS, laxatives are likely to work by increasing
stool volume and reducing gut transit time or by softening muco-
faeculant material that has built up in the gut. The passage of larger
volumes of more liquid stool may have a mechanical effect on any
adherent mucofaeces. However, the use of high doses of laxatives
are likely to lead to other undesirable consequences including the
unacceptable frequency of stooling, soiling, abdominal distension,
flatulence and abdominal pain.
Why it is important to do this review
Intestinal obstruction is an important and common problem in
CF. Incomplete DIOS is relatively common and there is consider-
able variation in practice. In our clinical experience, prophylaxis
for DIOS is given to individuals who have had an episode of com-
plete DIOS, those who have clinical signs consistent with incom-
plete DIOS or those with pancreatic insufficiency and clinical or
radiological manifestations of constipation (e.g. faecal masses pal-
pable on clinical examination or reported abdominal pain). The
evidence base for this practice is unclear and there is no clear ev-
idence base for any preventative therapies for DIOS (Colombo
2011).
Individuals with CF undergo a very large treatment burden. In dis-
cussing the risks and benefits of preventative treatment for DIOS
it is important that we give clear information about the likely side
effects and tolerability of any proposed therapy.
O B J E C T I V E S
This review aims to evaluate the effectiveness and safety of laxa-
tive agents of differing types for preventing DIOS (complete and
incomplete) in children and adults with CF. If possible, we aim to
assess the optimal laxative regimen by comparing the evidence for
osmotic laxatives, stimulant laxatives and mucolytic agents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised-controlled trials (RCT) and quasi-
RCTs. We will assess quasi-RCTs on their merit using the
Cochrane risk of bias tool and if both reviewers are satisfied that
the groups were similar at baseline, we will include them.
We will also assess cross-over trials for possible inclusion on an
individual basis. If we deem the treatment to alter the condition
to the extent that, on entry to subsequent phases, the participants
differ from their initial state, we will exclude the trial unless we
can use data from the first phase only (see Unit of analysis issues).
Types of participants
Children and adults with CF diagnosed by sweat test or genetic
testing, with all stages and severity of lung disease and with or
without pancreatic sufficiency.
Types of interventions
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We will compare the different treatment groups of enteral laxative
therapy for preventing DIOS (including osmotic agents, stimu-
lants, mucolytics and substances which have more than one ac-
tion) at any dose to placebo, no treatment or an alternative oral
laxative therapy.
As some treatments have significant overlap in their mechanisms
of action (e.g. Movicol® is a osmotic agent which also has a stim-
ulant effect), it is proposed that initial analysis will attempt to ex-
amine whether any preventative treatment is effective. The relative
effectiveness of different classes of agents will be examined as a
subgroup analysis.
Types of outcome measures
Primary outcomes
1. Complete or incomplete DIOS diagnosed either clinically
(e.g. abdominal masses, or distension or pain) or radiologically
(e.g. dilated bowel or faecal mass).
2. Adverse effects from treatments
i) serious adverse effects of treatment regimens
(including, but not limited to, rectal bleeding, intestinal
perforation, mucosal erosions, anaphylactic reaction, vomiting
with electrolyte disturbance)
ii) other adverse effects of treatment (e.g. diarrhoea or
soiling, abdominal distension, loss of continence or pain)
Secondary outcomes
1. Time to hospital admission
i) all causes
ii) due to DIOS
2. Patient-reported quality of life (QoL) scores
3. Patient-reported symptom scores
4. Tolerability (participant- or investigator-reported rates of
concordance)
Search methods for identification of studies
Electronic searches
We will identify relevant studies from the Group’s Cystic Fibrosis
Trials Register using the terms: distal intestinal obstruction syn-
drome [DIOS]. There will be no restrictions regarding language
or publication status.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cochrane Cystic
Fibrosis and Genetic Disorders Group website.
We will search the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
www.thecochranelibrary.com;
• MEDLINE Ovid (1946 onwards);
• Embase Ovid (1974 onwards).
We will also search the following trials registries and other re-
sources:
• US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov);
• International Standard Randomised Controlled Trial
Number (ISRCTN) Registry (www.isrctn.com);
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch);
• Open Grey (www.opengrey.eu/).
For details of our search strategies, please see the appendices (
Appendix 1).
Searching other resources
We will check the bibliographies of included trials and any rele-
vant systematic reviews identified for further references to relevant
trials.
Data collection and analysis
Selection of studies
Once we have the complete list of identified references, one au-
thor (WC) will check for and remove any duplicates. Two authors
(WC and JG) will then review all titles and abstracts and discard
references which clearly do not meet the inclusion criteria. We will
attempt to resolve any disagreements by discussion, but if we can
not reach a decision, we will ask the third author (FG) of the re-
view to mediate until we can reach a final decision. Once we have
discarded trials on the basis of title and abstract, we will obtain
full copies of the remaining references and screen these using a
standardised screening form customised for this review.
We will consider trials in any language and will translate them as
necessary. We will include trials published as full texts, but if where
there is only an abstract available, we will include it if it presents
results. If there are no results presented within the abstract or on
4Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
any trials registry sites, then we will classify the trial as ’Awaiting
assessment’ until more information is available. Similarly with un-
published trials, if a trial meets our inclusion criteria and quality
assessment then we will include it.
We will present the results of the search using a standardised flow
chart.
Data extraction and management
Two authors (WC and JG) will independently extract data using a
specially designed data extraction form developed by the Cochrane
Cystic Fibrosis and Genetic Disorders Review Group and adapted
to this review. We will collect data on:
• participant characteristics;
• trial characteristics and trial design;
• intervention and comparator;
• outcome data - we will report data for each outcome
separately.
One author (WC) will check the independent data extraction
forms for discrepancies and if there are any which we can not re-
solve by discussion, a third author (FG) will arbitrate.
We will enter the extracted data into the Review Manager software
for analysis (RevMan 2014). We initially will carry out the a com-
parison of any laxative agent versus placebo or usual treatment and
then, if possible, undertake subgroup analysis by type of laxative
(see Subgroup analysis and investigation of heterogeneity).
Assessment of risk of bias in included studies
We will use the risk of bias tool as described in the Cochrane Hand-
book for Systematic Reviews of Interventions to assess the risk of bias
across six domains (sequence generation, allocation concealment,
blinding, incomplete outcome data, selective reporting and other
potential sources of bias) (Higgins 2011).
If the trial describes the methods of randomisation and allocation,
including the concealment of the allocation sequence from the
researchers, and we deem these to be adequate, then we will rank
the trial as having a low risk of bias for this domain. Where these
are inadequate, we will rank the trial as being at a high risk and
where it is unclear from the description given, then we will rank
it as having an unclear risk of bias.
Similarly for blinding, we will look at the method used and who
was blinded to determine the risk of bias.
We will extract information on missing data and how the inves-
tigators recorded participant withdrawals and loss to follow up.
We will also look at whether missing data were equally distributed
between the intervention and control groups. If all review authors
agree that missing data have been accounted for adequately, then
we will judge the trial to be at a low risk of bias. We will record
the trial as having a high risk of bias if the missing data have not
been reported adequately and will record it as having an unclear
risk of bias if we are unable to see how the missing data have been
reported. Two authors will assess each included trial to determine
whether the investigators used an intention-to-treat (ITT) analysis
and again, once we have reached an agreement, we will rank the
trials as being at a high, low or unclear risk of bias.
If the trial investigators report all outcomes in the paper, the review
authors will record a low risk of bias from selective reporting. If
the paper states that investigators measured outcomes, but they
do not report the results of these, the review authors will rank the
paper as being at high risk. If it is unclear to the review authors
whether the trial reports all outcomes measured, then we will state
this and rank it as unclear for this domain. We will search for
trial protocols to be able to assess outcome reporting. If we can
not locate the protocol, we will assess outcome reporting based on
a comparison between the methods section of the full published
paper and the results section.
The review authors will look for any other potential sources of
bias in the included trials and will record what they find. If neither
author can find any other source of bias, then we will rank the trial
as having a low risk for this domain and high risk if the opposite
is true.
We will present the results of the risk of bias assessment both
individually and in a summary table.
Measures of treatment effect
For dichotomous data (complete DIOS, incomplete DIOS,
pooled adverse effects, failure to tolerate treatment and adherence),
we will calculate a pooled estimate of the treatment effects for each
outcome across trials using the risk ratio (RR) and 95% confidence
intervals (CIs) where appropriate. For individual adverse events,
e.g. reported soiling, then 99% CIs will be reported.
For continuous data (patient-reported QoL, symptom scores) we
plan to record the mean change and standard deviation (SD) from
baseline for each group. We intend to calculate a pooled estimate
of treatment effect using the mean difference (MD) and 95% CIs.
Where trials use different units of measurement or measurement
scales for reporting the same outcome (which is likely to be true
for QoL and symptom scores) we will use the standardised mean
difference (SMD) to report the results. Where trials only report
only a pre-intervention mean (SD) and post-intervention mean
(SD) then we can calculate the mean change but not the SD of
the change. We will report these results narratively.
For time-to-event data (e.g. time to hospitalisation) we will express
the intervention effect as a hazard ratio (HR) with 95% CIs using
the generic inverse variance method.
Where end-points are semantically different but report to similar
outcomes then we will group outcomes. Thus, synonymous terms
will be considered jointly. We will consider:
• abdominal distension (reported) to be synonymous with
bloating, swelling or gaseous distension;
• pain to be synonymous with discomfort or ache;
• vomiting to be synonymous with emesis;
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• constipation to be synonymous with straining or dyschezia.
Unit of analysis issues
We will assess any trials using a cross-over design to establish how
much data we can include in the analysis. Where the authors have
taken account of the cross-over design in the analysis, any carry-
over effect and within-person differences, we will be able to include
the trial. Where the data have not been analysed appropriately, we
may be able to include data from the first phase of the cross-over
trial as if it were a parallel design; although the advantage of the
cross-over design (using participants as their own controls) would
be lost (Elbourne 2002).
If we find trials which are multi-arm they will possibly fall into
more than one comparison. In such cases, where the two active
treatment arms are different types of laxative regimen, e.g. Movi-
col® versus lactulose and senna versus placebo, each treatment
arm will be analysed separately against placebo and where appro-
priate included in a meta-analysis. If the two active treatment arms
are of the same type of laxative (e.g. softening agents), but em-
ploy a different laxative or dose, we will combine them against the
placebo arm to look at the effect of the type of laxative rather than
an individual drug.
If there is heterogeneity between trials looking at different types of
laxative regimen, we will carry out a subgroup analysis to look at
the effect of individual drugs (Subgroup analysis and investigation
of heterogeneity).
Dealing with missing data
We will attempt to request additional data from the trial author(s)
if there are insufficient data in the published paper or uncertainty
about data we are able to extract from the included trials. We
will undertake an ITT analysis wherever possible throughout the
review.
We will also assess the extent to which trial authors have employed
an ITT analysis and we will report the numbers of participants
who dropped out of each arm of the trial, where possible.
Where data is incomplete but partially available we will use the
last available measurement to determine effectiveness.
Assessment of heterogeneity
Where there are trials reporting the same outcomes which we
are able to include in a meta-analysis, we will assess the level of
heterogeneity using the I² statistic. We will look at the overlap of
the CIs on the forest plots to gauge the significance of the I² value.
We will base our definitions of different levels of heterogeneity
on the levels described in the Cochrane Handbook for Systematic
Reviews of Interventions:
• low (might not be important) - 0% to 40%;
• moderate - 30% to 60%;
• substantial - 50% to 90%; and
• considerable - 75% to 100%.
The Cochrane Handbook for Systematic Reviews of Interventions
states that this is a rough guide because the importance of incon-
sistency depends on several factors (Deeks 2011).
Assessment of reporting biases
Where we are able to include at least 10 trials, we will generate
a funnel plot to attempt to identify any publication bias in the
included trials (Sterne 2011). We will also attempt to identify any
selective reporting in the included publications, by comparing the
trial protocols with the final papers and by careful examination
of the trial publications and consideration of reporting of both
positive and negative effects of the intervention. Where trial pro-
tocols are not available, we will compare the outcomes reported
in the results section against the methods section of the paper.
We will extract information on the sponsors, sources of funding
and competing interests of the authors to determine the role of
external bias being introduced. To minimise publication bias, we
will search trial registries and contact pharmaceutical companies
for unpublished data.
Data synthesis
Where we are able to combine trials in a meta-analysis, we will
use the data from the selected trials to generate forest plots using
the Review Manager software (RevMan 2014). We plan to carry
out an initial combined analysis of all types of laxative agent) fol-
lowed by separate meta-analyses for different groups of laxative
agents (e.g. osmotic laxatives, stimulants and those with a com-
bined mechanism of action) and mucolytics. We will examine the
level of heterogeneity to determine which type of analysis model
to use. If there is low heterogeneity (less than 40%) then we will
use a fixed-effect model and if the I² statistic is greater than 40%
then we will use a random-effects model to summarize the data.
Subgroup analysis and investigation of heterogeneity
If there is greater than 40% heterogeneity among the included
trials, we will undertake subgroup analyses to look at the following:
• children (18 years and under) versus adults;
• type of laxative (osmotic agent (e.g. lactulose) versus
stimulant laxative regimes (e.g. senna) versus mucolytic (e.g. N-
acetylcysteine));
• single regimens versus combined regimens (e.g. lactulose
and senna)
• effectiveness of regimen in preventing complete versus
incomplete DIOS* (Houwen 2010)
*The following definitions of complete and incomplete DIOS are
taken from (Houwen 2010).
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1. Complete intestinal obstruction as evidenced by vomiting
of bilious material and/or fluid levels in small intestine on an
abdominal radiography.
2. Faecal mass in ileo-caecum.
3. Abdominal pain or distension (or both).
Complete DIOS is defined as when all three of the above criteria
are present, whereas incomplete or impending DIOS is defined as
only the second and third criteria being present.
Sensitivity analysis
Where we have performed a meta-analysis, we will carry out sen-
sitivity analyses to look at the effect of the risk of bias findings. We
will look at the effect of adding in and taking out trials where there
is high risk of bias. We will also attempt to examine the effect of
cross-over trials on the results by carrying out a sensitivity analysis
to include and exclude them.
Summary of findings table
We will report summary of findings information, with a separate
table for each treatment comparison, for our chosen outcomes
comparing laxative agents versus control, placebo or alternate reg-
imens for the outcomes: prevention of complete or incomplete
DIOS, adverse events, hospitalisation for any cause, hospitalisa-
tion for DIOS, QoL, symptom score, and tolerability. Where no
data for individual outcomes are available then a row in the table
will identify this by entry of the notation: ’data not reported’.
For each outcome we will report the illustrative risk with and with-
out the intervention, magnitude of effect (RR or MD), numbers
of trials and participants addressing each outcome and a grade
of the overall quality of the body of evidence using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) with comments (Schunemann 2006).
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A P P E N D I C E S
Appendix 1. Search strategies
Database/Resource Strategy
Cochrane Central Register of Controlled Trials (CENTRAL) #1 Cystic Fibrosis [MeSH descriptor]
#2 cystic fibrosis:ti,ab
#3 fibrocystic near/10 disease near/10 pancreas
#4 mucoviscidos*:ti,ab
#5 cystic* near/10 fibros*:ti,ab
#6 #1 or #2 or #3 or #4 or #5
#7 distal intestinal obstruction syndrome*:ti,ab
#8 dios or mie:ti,ab
#9 Intestinal Obstruction [MeSH descriptor]
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(Continued)
#10 meconium ileus equivalent:ti,ab
#11 faecal near/3 (obstruction or impact*):ti,ab
#12 Constipation [MeSH descriptor]
#13 constipat*:ti,ab
#14 laxative*:ti,ab
#15 Laxatives [MeSH descriptor]
#16 lactulose:ti,ab
#17 Lactulose [MeSH descriptor]
#18 (macrogol or polyethylene glycol*):ti,ab












#31 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #
16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
or #26 or #27 or #28 or #29 #30
#32 #6 and #31
MEDLINE Ovid (1946 onwards) 1. Cystic Fibrosis/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. “distal intestinal obstruction syndrome*”.tw.
8. (dios or mie).tw.
9. Intestinal Obstruction/
10. meconium ileus equivalent.tw.





16. lactulose.tw. or Lactulose/
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(Continued)
24. bicosulfate.tw.




29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 6 and 29
Embase Ovid (1974 onwards) 1. CYSTIC FIBROSIS/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. “distal intestinal obstruction syndrome*”.tw.
8. (dios or mie).tw.
9. INTESTINE OBSTRUCTION/
10. meconium ileus equivalent.tw.





16. lactulose.tw. or LACTULOSE/












29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 6 and 29
Clinicaltrials.gov ADVANCED SEARCH
Search 1
Search terms: laxative OR laxatives OR lactulose OR macrogol OR
polyethylene OR movicol OR klean OR diatriozate OR gastrografin
OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol
OR parvolex OR picosulphate OR fibre
Study type: Interventional Studies
Conditions: cystic fibrosis
Search 2
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(Continued)
Search terms: intestinal OR DIOS OR constipation OR constipated
OR faecal OR meconium
Study type: Interventional Studies
Conditions: cystic fibrosis
ISRCTN Registry ADVANCED SEARCH
Condition: cystic fibrosis
WHO ICTRP BASIC SEARCHES
Search 1: cystic fibrosis AND intestinal
Search 2: cystic fibrosis AND constipation
Search 3: cystic fibrosis AND faecal




Intervention: laxative OR laxatives OR lactulose OR macrogol OR
polyethylene OR movicol OR klean OR diatriozate OR gastrografin
OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol
OR parvolex OR picosulphate OR fibre
Recruitment Status: All
Open Grey (cystic fibrosis OR cf OR mucoviscidos*) AND (intestin* OR con-
stipat* OR faecal OR meconium OR laxative* OR lactulose OR
macrogol OR polyethylene OR movicol OR klean* OR diatriozate
OR gastrografin OR senna OR docusate OR bicosulfate OR acetyl-
cysteine OR fibrol OR parvolex OR picosulphate OR fibre)
C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol WC
Review stage: select which trials to include (2 + 1 arbiter) JG + WC + FG as arbiter
Review stage: extract data from trials (2 people) JG + WC
Review stage: enter data into RevMan JG
Review stage: carry out the analysis JG + WC
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Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Review stage: interpret the analysis JG + WC
Review stage: draft the final review JG + WC
Update stage: update the review WC
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Summary of findings:  
Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic 
fibrosis 
Patient or population: preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis  
Setting: Tertiary Centre  
Intervention: Cisapride  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 
























to 6 months  




(1 RCT)  ⨁◯◯◯ 
VERY LOW 
a,b,c 
Radiologist scored for 








months to 12 
months  
No adverse effects were noted.  
 
34 

















months to 12 
months  





The mean total 
gastrointestinal symptom 
scores in the intervention 
group was 7.6 lower (14.73 
lower to 0.47 higher)  
-  34 
(1 RCT)  ⨁◯◯◯ 
VERY LOW 
b,c,d 





abdominal pain, diarrhoea, 
nausea, vomiting, anorexia.  
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Summary of findings:  
Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic 
fibrosis 
Patient or population: preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis  
Setting: Tertiary Centre  
Intervention: Cisapride  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 





























scores was 5.9  
The mean abdominal pain 
symptom scores in the 
intervention group was 0.4 
lower (2.05 lower to 1.25 
higher)  
-  34 























scores was 4.4  
The mean abdominal 
distension symptom scores 
in the intervention group was 
0.9 lower (2.39 lower to 0.59 
higher)  
-  34 

















to 6 months  
With placebo: 3 felt better, 2 felt the same, 12 
felt worse. With cisapride: 12 felt better, 2 felt 
the same, 3 felt worse. p<0.05  
 
34 




*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; MD: Mean difference  
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Summary of findings:  
Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic 
fibrosis 
Patient or population: preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis  
Setting: Tertiary Centre  
Intervention: Cisapride  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 











Risk with Cisapride 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Selective reporting may have occurred with this outcome. Allocation concealment and sequence generation was unclear  
b. Cisapride is a prokinetic, not a typical laxative agent (Different to protocol). The study was conducted in 1990 when cisapride was still prescribed. It 
has now been taken out of the UK market and other international markets due to its rare but serious cardiac effects.  
c. Very small number of participants in the study does not give sufficient information to give a precise effect estimate.  
d. Allocation concealment and sequence generation ranked as unclear risk of bias  
e. Allocation concealment and sequence generation ranked as unclear risk of bias. Physicians were also outcome assessors for this outcome, but 














































Q4	Warren	 is	 a	 10-year	 old	 boy	with	 CF.	 He	 is	 homozygous	 Phe508del	 and	 pancreatic	
insufficient.		 	He	has	 intermittent	 lower	abdominal	pain.	He	 reports	opening	his	bowels	
twice	 per	 day,	 passing	 normal,	 formed	 stools	without	 difficulty.	 His	 adherence	with	 all	
treatments	is	good.			On	examination	you	identify	a	6x4cm,	indentable	mass	in	the	right	
iliac	 fossa.	 His	 abdomen	 is	 not	 distended	 and	 bowel	 sounds	 are	 normal.	 You	 make	 a	








































































Institutions:	 1Institute	 of	 Applied	 Clinical	 Science,	 Keele	 University,	 ST4	 7QB,	 UK;	
2University	Hospitals	of	North	Staffordshire	NHS	Trust,	Stoke	on	Trent,	ST4	6QG,	UK.	
Correspondence:	Dr	 Francis	 J	Gilchrist,	Department	 of	 Paediatric	 Respiratory	Medicine,	
Royal	 Stoke	 University	 Hospital,	 University	 Hospitals	 of	 North	 Staffordshire	 NHS	 Trust,	























constipation	and	distal	 intestinal	obstruction	 syndrome	 (DIOS)	management.	 	 Response	
rate	was	 55%	 (81/147).	Movicol®	 and	 lifestyle	modification	 accounted	 for	 >70%	of	 the	
interventions	 used	 for	 constipation.	 Adult	 physicians	 used	 a	 higher	 median	 (range)	
number	 of	 interventions	 for	 constipation	 per	 patient;	 2	 (1-3)	 vs	 1	 (1-2),	 p=0.006.	 	 For	
incomplete	 DIOS,	 nine	 interventions,	 combined	 into	 22	 different	 regimens	 were	 used.		
The	 most	 common	 were	 Movicol®,	 Gastrografin®	 and	 lifestyle	 modification.	 	 Adult	
physicians	 were	 more	 likely	 to	 use	 Gastrografin®	 (p=0.01).	 For	 complete	 DIOS,	
Gastrografin®,	 KleanPrep®	 and	 surgical	 review	 were	 the	 most	 common	 interventions.		
Paediatricians	were	more	 likely	 to	 request	 surgical	 review	 (p=0.01).	 	 In	 summary,	 there	
was	 relatively	 little	 variation	 in	 the	management	 of	 constipation.	 	 However,	 there	was	











the	 ileocaecum	whereas	 constipation	 is	 gradual	 faecal	 impaction	 of	 the	 total	 colon.[4]	




Separate	electronic	 surveys	were	devised	 to	clarify	 the	 first	and	second-line	 treatments	
for	 constipation,	 partial	 DIOS	 and	 complete	 DIOS	 used	 by	 paediatricians	 and	 adult	
physicians.	These	were	based	around	case	vignettes	of	patients	who	met	the	diagnostic	
criteria	 for	 these	 conditions	 as	 defined	 by	 the	 European	 Society	 for	 Paediatric	
Gastroenterology,	 Hepatology	 and	 Nutrition	 CF	 Working	 Group.[4]	 The	 surveys	 are	
available	 in	 Appendix	 1.	 	 A	 link	 to	 the	 appropriate	 surveys	was	 sent	 via	 email	 to	 each	







significant.	 	 All	 statistical	 analyses	 were	 undertaken	 using	 STATA	 version	 12.0	 (STATA	
Corp,	 Texas,	 USA).	 	 The	 UK	 NHS	 Health	 Research	 Authority	 ethics	 tool	 confirmed	 that	







Free	 text-responses	 related	 to	 fluid	 intake,	 exercise	 and	 adherence	 were	 grouped	 as	
“lifestyle	modification”	 and	 those	which	 included	 nil	 by	mouth,	 IV	 fluids	 or	 nasogastric	
tube	were	grouped	into	“drip	and	suck”.	
Constipation	
All	 respondents	 completed	 this	 question.	 	 The	 adult	 physicians	 used	 a	 higher	 median	
(range)	 number	 of	 interventions	 per	 patient	 than	 paediatricians;	 2	 (1-3)	 vs	 1	 (1-2),	
p=0.006.	 	Responses	are	summarised	 in	Figure	1.	 	Sachets	of	Macrogol	3350	(Movicol®)	
and	lifestyle	modifications	accounted	for	>70%	of	the	responses	from	both	paediatricians	
and	adult	physicians.	 	 Lactulose	was	 the	only	other	 intervention	used	by	paediatricians	











22	 different	 regimens	 by	 the	 paediatricians	 and	 23	 different	 regimens	 by	 the	 adult	
physicians.	 	The	three	most	commonly	used	interventions	were	Movicol®,	Gastrografin®	
and	 lifestyle	 modification.	 	 Adult	 physicians	 were	 more	 likely	 to	 use	 Gastrografin®	
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for	 children	 and	 adults	 with	 CF	 across	 the	 UK.	 	 The	 surveys	 were	 distributed	 to	 the	
majority	of	paediatricians	and	adult	physicians	working	at	 tertiary	CF	centres	 in	 the	UK.		
The	 wide	 distribution	 and	 satisfactory	 response	 rate	means	 that	 we	 are	 confident	 the	
survey	accurately	reflects	current	UK	practice.			
There	 was	 relatively	 little	 variation	 in	 the	management	 of	 constipation	 in	 CF	 amongst	
both	adult	physicians	and	paediatricians.	 	Although	eight	different	therapies	were	 listed	
the	 vast	majority	of	 respondents	used	macrogol	 3350	and	 /	or	 lifestyle	modification	as	
their	first	line	treatment.		Paediatricians	only	listed	one	additional	treatment	option.		This	
consensus	 is	 likely	 to	be	 influenced	by	 the	national	 guidance	available	 for	 constipation,	
informed	by	randomised	controlled	trials.[5]	Although	the	NICE	guideline	is	not	specific	to	
cystic	fibrosis,	there	is	no	reason	to	think	that	this	guidance	cannot	be	extrapolated	to	CF.		














was	 noted	 amongst	 both	 the	 paediatricians	 and	 adult	 physicians.	 	 The	 listed	 medical	
therapies	 included	both	 laxatives	used	 for	 constipation	and	 the	bowel	 cleansing	agents	
used	to	treat	complete	DIOS.		Previously	published	guidelines	have	advocated	the	use	of	
Movicol®	as	first	line	treatment	for	incomplete	DIOS	and	gastrografin®	as	second	line.[7]				
This	 survey	 has	 highlighted	wide	 variation	 in	 the	 treatment	 regimens	 used	 in	 DIOS	 for	
children	and	adults.		This	was	most	noticeable	for	incomplete	DIOS.		A	lack	of	good	quality	
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Appendix	6:	Certificates	of	attendance	from	the	Cochrane	Review	Author	
training	courses.	




